NDC 55513-954

Vectibix

Panitumumab

Vectibix is a Intravenous Solution in the Human Prescription Drug category. It is labeled and distributed by Amgen Inc. The primary component is Panitumumab.

• Product ID: 55513-954_27e8fc71-845b-46d0-a7d5-8a684380fa9d
• NDC: 55513-954
• Product Type: Human Prescription Drug
• Proprietary Name: Vectibix
• Generic Name: Panitumumab
• Dosage Form: Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2006-10-10
• Marketing Category: BLA / BLA
• Application Number: BLA125147
• Labeler Name: Amgen Inc
• Substance Name: PANITUMUMAB
• Active Ingredient Strength: 100 mg/5mL
• Pharm Classes: HER1 Antagonists [MoA],Antibodies, Monoclonal [CS],Epidermal Growth Factor Receptor Antagonist [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 55513-954-01

1 VIAL, SINGLE-DOSE in 1 CARTON (55513-954-01) > 5 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2006-10-10
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 55513-954-01 [55513095401]

Vectibix SOLUTION

• Marketing Category: BLA
• Application Number: BLA125147
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2006-10-10

Drug Details

Active Ingredients

Ingredient	Strength
PANITUMUMAB	100 mg/5mL

OpenFDA Data

• SPL SET ID: e0fa4bca-f245-4d92-ae29-b0c630a315c2
• Manufacturer:
  • Amgen Inc
• UNII:
  • 6A901E312A
• RxNorm Concept Unique ID - RxCUI:
  • 1657703
  • 1657723
  • 1657705
  • 1657722

Pharmacological Class

• HER1 Antagonists [MoA]
• Antibodies
• Monoclonal [CS]
• Epidermal Growth Factor Receptor Antagonist [EPC]

NDC Crossover Matching brand name "Vectibix" or generic name "Panitumumab"

NDC	Brand Name	Generic Name
55513-954	Vectibix	panitumumab
55513-956	Vectibix	panitumumab